CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.
The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
CEO Kim Popovits discussed three strategic imperatives for the coming year: increasing penetration in established markets, broadening global access, and continuing to diversify its portfolio.
Stat News notes that, this year, female presenters at the JP Morgan Healthcare Conference will actually outnumber those named Michael.
The company is aiming to make its Digital Spatial Profiling technology compatible with NGS and will present customer data from its Hyb & Seq at AGBT.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.